top of page

Familial Hypercholesterolemia

= ILF Board Member Author(s)

Low Density Lipoprotein Receptor.jpg

Functional analysis of new variants at the Low Density Lipoprotein Receptor associated with familial hypercholesterolemia


Analysis of S100A12 plasma levels in hyperlipidemic subjects with or without familial hypercholesterolemia

triglycerides oct18.jpg

Review of the long-term safety of lomitapide: a microsomal triglycerides transfer protein inhibitor for treating homozygous familial hypercholesterolemia


Genetic Testing and Risk Scores: Impact on Familial Hypercholesterolemia


Efficacy, safety, and tolerability of evolocumab in pediatric patients with heterozygous familial hypercholesterolemia: Rationale and design of the HAUSER-RCT study.

perc coron int.jpg

Percutaneous Coronary Intervention in Familial Hypercholesterolemia Is Understudied


Clinical Genetic Testing for Familial Hypercholesterolemia: JACC Scientific Expert Panel.


Simplified Canadian Definition for Familial Hypercholesterolemia.

high ldl.jpg

Performance of LDL-C calculated with Martin's formula compared to the Friedewald equation in familial combined hyperlipidemia.

lipid clinic.jpg

Familial hypercholesterolemia: Experience in the Lipid Clinic of Alava.


Target achievement and cardiovascular event rates with Lomitapide in homozygous Familial Hypercholesterolaemia.


Prediction of subtle left ventricular systolic dysfunction in homozygous and heterozygous familial hypercholesterolemia: Genetic analyses and speckle tracking echocardiography study.


Guidelines for Diagnosis and Treatment of Familial Hypercholesterolemia 2017.

Evolocumab and lipoprotein apheresis combination therapy may have synergic effects to reduce low-density lipoprotein cholesterol levels in heterozygous familial hypercholesterolemia: A case report.

Impact of age on excess risk of coronary heart disease in patients with familial hypercholesterolaemia

Remnant-like particles and coronary artery disease in familial hypercholesterolemia.

Lipoprotein(a) level associates with coronary artery disease rather than carotid lesions in patients with familial hypercholesterolemia.

2017 Update of ESC/EAS Task Force on practical clinical guidance for proprotein convertase subtilisin/kexin type 9 inhibition in patients with atherosclerotic cardiovascular disease or in familial hypercholesterolaemia

Guidance for Pediatric Familial Hypercholesterolemia 2017.

A comparative analysis of phenotypic predictors of mutations in familial hypercholesterolemia.

Familial Hypercholesterolemia: Cascade Screening in Children and Relatives of the Affected.

High serum triglyceride concentrations in patients with homozygous familial hypercholesterolemia attenuate the efficacy of lipoprotein apheresis by dextran sulfate adsorption.

Lipoprotein profile assessed by 2D-1H-NMR and subclinical atherosclerosis in children with familial hypercholesterolaemia.

bottom of page